Annabel Samimy

In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on Corcept Therapeutics (NASDAQ: CORT). In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates...

In a report published Monday, Stifel analyst Annabel Samimy downgraded Corcept Therapeutics Incorporated (NASDAQ: CORT) to Hold. According to the report, CORT is making gradual progress with its Korlym (mifepristone) launch. However, 1.5 years since launch, Korlym adoption in Cushing's syndrome...

In a report published Tuesday, Stifel analyst Annabel Samimy downgraded the rating on Santarus (NASDAQ: SNTS) from Buy to Hold, and removed the $27.00 price target. In the report, Stifel noted, “Following the acquisition announcement by Salix at $32/share, we are downgrading SNTS to Hold. This...

In a report published Tuesday, Stifel analyst Annabel Samimy upgraded the rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) from Hold to Buy, and named a $108.00 price target. In the report, Stifel noted, “Following a thorough strategic/financial analysis of SLXP's $2.6bn acquisition of SNTS, we...

In a report published Thursday, Stifel analyst Annabel Samimy reiterated a Buy rating on Perrigo Company (NYSE: PRGO), and raised the price target from $150.00 to $165.00. In the report, Stifel noted, “PRGO shares have appreciated nearly 30% since late August, after pulling back following...

In a report published Wednesday, Stifel analyst Annabel Samimy initiated coverage on Alcobra (NASDAQ: ADHD) with a Buy rating and $27.00 price target. In the report, Stifel noted, “We are initiating coverage of Alcobra Ltd. with a Buy rating and $27 target price. Alcobra is developing novel and...

In a report published Tuesday, Stifel analyst Annabel Samimy initiated coverage on Aerie Pharmaceuticals (NASDAQ: AERI) with a Buy rating and $18.00 price target. In the report, Stifel noted, “We are initiating coverage of Aerie Pharmaceuticals, Inc. (AERI) with a Buy rating on the shares and an $...

In a report published Tuesday, Stifel analyst Annabel Samimy upgraded the rating on Zogenix (NASDAQ: ZGNX) from Hold to Buy, and named a $5.00 price target. In the report, Stifel noted, “Following Zohydro's approval Friday, Zogenix updated its commercialization/partnership plans going forward....

In a report published Wednesday, Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and raised the price target from $80.00 to $85.00. In the report, Stifel Nicolaus noted, “2Q13 revenues were in-line ($208.3mn vs Consensus $208.7mn) with...

In a report published Tuesday, Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Perrigo (NYSE: PRGO), and raised the price target from $125.00 to $145.00. In the report, Stifel Nicolaus noted, “Perrigo is acquiring Irish-domiciled Elan for $8.6bn ($16.50/share, cash and equity...

In a report published Monday, Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Santarus (NASDAQ: SNTS), and raised the price target from $22.00 to $24.00. In the report, Stifel Nicolaus noted, “With Uceris (induction of remission, active mild-moderate ulcerative colitis/UC)...

In a report published Thursday, Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $36.00 to $40.00. In the report, Stifel Nicolaus noted, “Following May's Opana ER setback and management reshuffling, Endo...

In a report published Friday, Stifel Nicolaus analyst Annabel Samimy initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $80.00 price target. In the report, Stifel Nicolaus noted, “We are initiating coverage on Jazz Pharmaceuticals with a Buy rating on the shares and...